Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04677569




Registration number
NCT04677569
Ethics application status
Date submitted
16/12/2020
Date registered
21/12/2020

Titles & IDs
Public title
Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex
Scientific title
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC)
Secondary ID [1] 0 0
2020-003079-16
Secondary ID [2] 0 0
INS-416
Universal Trial Number (UTN)
Trial acronym
ENCORE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Mycobacterium Infections, Nontuberculous 0 0
Condition category
Condition code
Infection 0 0 0 0
Studies of infection and infectious agents
Infection 0 0 0 0
Other infectious diseases
Infection 0 0 0 0
Sexually transmitted infections

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - ALIS
Treatment: Drugs - Azithromycin
Treatment: Drugs - Ethambutol
Treatment: Drugs - ELC (matching placebo for ALIS)

Experimental: ALIS + Background Regimen - Participants will be administered 590 mg of ALIS (amikacin liposome inhalation suspension) once daily. Participants will also be administered azithromycin 250 mg and ethambutol 15 mg/kg, once daily.

Placebo comparator: ELC + Background Regimen - Participants will be administered ELC (empty liposome control), a visually matching placebo to ALIS (amikacin liposome inhalation suspension), once daily. Participants will also be administered azithromycin 250 mg and ETH (ethambutol) 15 mg/kg, once daily.


Treatment: Drugs: ALIS
Inhalation via nebulization over approximately 6 to 15 minutes

Treatment: Drugs: Azithromycin
Oral tablet

Treatment: Drugs: Ethambutol
Oral tablet

Treatment: Drugs: ELC (matching placebo for ALIS)
Inhalation via nebulization over approximately 6 to 15 minutes
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change from Baseline in Respiratory Symptom Score at Month 13
Timepoint [1] 0 0
Baseline to Month 13
Secondary outcome [1] 0 0
Percentage of Participants Achieving Durable Culture Conversion at Month 15
Timepoint [1] 0 0
Month 15
Secondary outcome [2] 0 0
Change from Baseline in Fatigue Symptom Score at Month 13
Timepoint [2] 0 0
Baseline to Month 13
Secondary outcome [3] 0 0
Percentage of Participants Achieving Culture Conversion by Month 6
Timepoint [3] 0 0
Month 6
Secondary outcome [4] 0 0
Percentage of Participants Achieving Culture Conversion by Month 12
Timepoint [4] 0 0
Month 12
Secondary outcome [5] 0 0
Percentage of Participants Achieving Culture Conversion by Month 13
Timepoint [5] 0 0
Month 13
Secondary outcome [6] 0 0
Percentage of Participants Achieving Culture Conversion During Treatment
Timepoint [6] 0 0
Baseline to Month 12
Secondary outcome [7] 0 0
Time to Culture Conversion
Timepoint [7] 0 0
Baseline to Month 12
Secondary outcome [8] 0 0
Time to the First Negative Culture
Timepoint [8] 0 0
Baseline to Month 12
Secondary outcome [9] 0 0
Percentage of Participants Who Develop a Mycobacterium avium Complex (MAC) Isolate with Amikacin Minimum Inhibitory Concentration (MIC) = 128 µg/mL More Than One Time
Timepoint [9] 0 0
Baseline to Month 15
Secondary outcome [10] 0 0
Percentage of Participants Achieving Culture Conversion and a Subsequent at Least one MAC Positive Culture in Agar Media or Broth Media in at Least 2 Consecutive Visits With Matching Species and Genome at Screening/ Baseline
Timepoint [10] 0 0
Baseline to Month 15
Secondary outcome [11] 0 0
Percentage of Participants Achieving Culture Conversion and a Subsequently have at least One MAC Positive Culture in Agar Media or Broth Media in at Least 2 Consecutive Visits With Differing Species and/or Genome at Screening/ Baseline
Timepoint [11] 0 0
Baseline to Month 15
Secondary outcome [12] 0 0
Percentage of Participants Meeting the Within-subject Meaningful Change Threshold as Reflected in the Change in Respiratory Symptom Scores Computed From Baseline to Month 13
Timepoint [12] 0 0
Baseline to Month 13
Secondary outcome [13] 0 0
Number of Participants Who Experience an Adverse Event (AEs)
Timepoint [13] 0 0
Baseline to Month 15

Eligibility
Key inclusion criteria
* Male or female, = 18 years of age (19 years or older in South Korea, 20 years or older in Japan).
* Current diagnosis of MAC lung infection. MAC or mixed infection with MAC as the dominant species is allowed, with MAC as the intended organism for treatment.
* A chest computerized tomography (CT) scan, read locally, within 6 months prior to Screening to determine presence and size of pulmonary cavities. Participants who do not have a chest CT scan within 6 months prior to Screening will be required to obtain a chest CT scan, read locally, during Screening.
* Willingness and ability to adhere to prescribed study treatment during the study.
* Women of childbearing potential (WOCBP) (ie, fertile following menarche and until becoming postmenopausal unless permanently sterile) and fertile men (ie, all men after puberty unless permanently sterile by bilateral orchidectomy) agree to practice a highly effective method of birth control from Day 1 to at least 90 days after the last dose. Examples of such birth controls are:

* true abstinence (refraining from heterosexual intercourse during the entire study),
* copper intrauterine device (IUD),
* hormonal methods (levonorgestrel-releasing intrauterine system, progestogen implant, combined oral contraceptive pill [combined with barrier method]),
* exclusive homosexual relationship, or
* sole male partner who has undergone surgical sterilization with confirmation of azoospermia at least 3 months post procedure.
* Provide signed informed consent prior to administration of study drugs or performing any study-related procedure.
* Be able to comply with study drugs use, study visits, and study procedures as defined by the protocol.
* Men with partners who are WOCBP (pregnant or non-pregnant) agree to use condoms and non-pregnant partners should practice a highly effective method of birth control
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Diagnosis of cystic fibrosis (CF).
* History of more than 3 MAC lung infections (a 4th MAC lung infection is not eligible)
* Received any mycobacterial antibiotic treatment for current MAC lung infection
* Refractory MAC lung infection, defined as having positive MAC cultures while being treated with a multidrug mycobacterial antibiotic treatment regimen for a minimum of 6 consecutive months and no documented successful treatment, defined as negative sputum culture for MAC and cessation of treatment
* Relapse of prior MAC lung infection, defined as positive sputum culture for MAC =6 months of cessation of prior successful treatment
* Evidence of any pulmonary cavity = 2 cm in diameter, as determined by chest CT scan, read locally, during Screening or within 6 months prior to Screening
* Radiographic finding of new lobar consolidation, atelectasis, significant pleural effusion, or pneumothorax during routine clinical care within 2 months prior to Screening
* Active pulmonary malignancy (primary or metastatic) or any malignancy requiring chemotherapy or radiation therapy within 1 year prior to Screening or anticipated during the study
* Acute pulmonary exacerbation (eg, chronic obstructive pulmonary disease (COPD) or bronchiectasis) requiring treatment with antibiotics, or corticosteroids (intravenous [IV] or oral), within 4 weeks prior to and during Screening
* Current smoker
* History of lung transplantation
* Prior exposure to ALIS (including clinical study)
* Known hypersensitivity or contraindications to use to ALIS, aminoglycosides, or any of their excipients
* Disseminated MAC infection
* Administration of any investigational drug within 8 weeks prior to Screening
* Known or suspected acquired immunodeficiency syndromes (Human Immunodeficiency Virus (HIV) -positive, regardless of CD4 counts). Other immunodeficiency syndromes that may interfere with study participation in the opinion of the Investigator
* Current alcohol, medication, or illicit drug abuse
* Known and active COVID-19 infection
* Known hypersensitivity or contraindications to use of ethambutol, azithromycin (including other macrolides or ketolides), or any of their excipients per local labeling guidance.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/04/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
15/01/2026
Actual
Sample size
Target
Accrual to date
Final
425
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Recruitment hospital [1] 0 0
AUS006 - Concord
Recruitment hospital [2] 0 0
AUS012 - Birtinya
Recruitment hospital [3] 0 0
AUS010 - Chermside
Recruitment hospital [4] 0 0
AUS013 - Douglas
Recruitment hospital [5] 0 0
AUS003 - Greenslopes
Recruitment hospital [6] 0 0
AUS016 - Herston
Recruitment hospital [7] 0 0
AUS014 - Meadowbrook
Recruitment hospital [8] 0 0
AUS011 - Woolloongabba
Recruitment hospital [9] 0 0
AUS008 - Adelaide
Recruitment hospital [10] 0 0
AUS007 - Clayton
Recruitment hospital [11] 0 0
AUS005 - Perth
Recruitment postcode(s) [1] 0 0
2139 - Concord
Recruitment postcode(s) [2] 0 0
4575 - Birtinya
Recruitment postcode(s) [3] 0 0
4032 - Chermside
Recruitment postcode(s) [4] 0 0
4814 - Douglas
Recruitment postcode(s) [5] 0 0
4120 - Greenslopes
Recruitment postcode(s) [6] 0 0
4029 - Herston
Recruitment postcode(s) [7] 0 0
4131 - Meadowbrook
Recruitment postcode(s) [8] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [9] 0 0
5000 - Adelaide
Recruitment postcode(s) [10] 0 0
3168 - Clayton
Recruitment postcode(s) [11] 0 0
5000 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
District of Columbia
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Idaho
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Kansas
Country [8] 0 0
United States of America
State/province [8] 0 0
Louisiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
Minnesota
Country [11] 0 0
United States of America
State/province [11] 0 0
Missouri
Country [12] 0 0
United States of America
State/province [12] 0 0
Nebraska
Country [13] 0 0
United States of America
State/province [13] 0 0
New Jersey
Country [14] 0 0
United States of America
State/province [14] 0 0
New York
Country [15] 0 0
United States of America
State/province [15] 0 0
Ohio
Country [16] 0 0
United States of America
State/province [16] 0 0
Pennsylvania
Country [17] 0 0
United States of America
State/province [17] 0 0
Rhode Island
Country [18] 0 0
United States of America
State/province [18] 0 0
South Carolina
Country [19] 0 0
United States of America
State/province [19] 0 0
Tennessee
Country [20] 0 0
United States of America
State/province [20] 0 0
Texas
Country [21] 0 0
United States of America
State/province [21] 0 0
Virginia
Country [22] 0 0
Argentina
State/province [22] 0 0
Tucumán
Country [23] 0 0
Austria
State/province [23] 0 0
Oberösterreich
Country [24] 0 0
Belgium
State/province [24] 0 0
Brussels
Country [25] 0 0
Belgium
State/province [25] 0 0
Ghent
Country [26] 0 0
Belgium
State/province [26] 0 0
Leuven
Country [27] 0 0
Canada
State/province [27] 0 0
Manitoba
Country [28] 0 0
Canada
State/province [28] 0 0
Ontario
Country [29] 0 0
Chile
State/province [29] 0 0
Maule
Country [30] 0 0
Chile
State/province [30] 0 0
Quillota
Country [31] 0 0
Chile
State/province [31] 0 0
Valparaíso
Country [32] 0 0
Denmark
State/province [32] 0 0
South Denmark
Country [33] 0 0
Denmark
State/province [33] 0 0
Aalborg
Country [34] 0 0
Denmark
State/province [34] 0 0
Odensa C
Country [35] 0 0
France
State/province [35] 0 0
Bas-Rhin
Country [36] 0 0
France
State/province [36] 0 0
Gironde
Country [37] 0 0
France
State/province [37] 0 0
Loire-Atlantique
Country [38] 0 0
France
State/province [38] 0 0
Amiens cedex 1
Country [39] 0 0
France
State/province [39] 0 0
Marseille
Country [40] 0 0
France
State/province [40] 0 0
Paris
Country [41] 0 0
France
State/province [41] 0 0
Saint Denis Cedex
Country [42] 0 0
France
State/province [42] 0 0
Saint Pierre
Country [43] 0 0
Germany
State/province [43] 0 0
Bayern
Country [44] 0 0
Germany
State/province [44] 0 0
Nordrhein-Westfalen
Country [45] 0 0
Germany
State/province [45] 0 0
Berlin
Country [46] 0 0
Germany
State/province [46] 0 0
Essen
Country [47] 0 0
Germany
State/province [47] 0 0
Hannover
Country [48] 0 0
Greece
State/province [48] 0 0
Attiki
Country [49] 0 0
Hungary
State/province [49] 0 0
Budapest
Country [50] 0 0
Israel
State/province [50] 0 0
Tel-Aviv
Country [51] 0 0
Israel
State/province [51] 0 0
Ashkelon
Country [52] 0 0
Israel
State/province [52] 0 0
Haifa
Country [53] 0 0
Israel
State/province [53] 0 0
Jerusalem
Country [54] 0 0
Israel
State/province [54] 0 0
Petah Tikva
Country [55] 0 0
Israel
State/province [55] 0 0
Ramat Gan
Country [56] 0 0
Italy
State/province [56] 0 0
Emilia-Romagna
Country [57] 0 0
Italy
State/province [57] 0 0
Liguria
Country [58] 0 0
Italy
State/province [58] 0 0
Firenze
Country [59] 0 0
Italy
State/province [59] 0 0
Milano
Country [60] 0 0
Italy
State/province [60] 0 0
Monza
Country [61] 0 0
Italy
State/province [61] 0 0
Pavia
Country [62] 0 0
Italy
State/province [62] 0 0
Roma
Country [63] 0 0
Japan
State/province [63] 0 0
Aiti
Country [64] 0 0
Japan
State/province [64] 0 0
Hukuoka
Country [65] 0 0
Japan
State/province [65] 0 0
Kanagawa
Country [66] 0 0
Japan
State/province [66] 0 0
Mie
Country [67] 0 0
Japan
State/province [67] 0 0
Nagasaki
Country [68] 0 0
Japan
State/province [68] 0 0
Okayama
Country [69] 0 0
Japan
State/province [69] 0 0
Simane
Country [70] 0 0
Japan
State/province [70] 0 0
Sizuoka
Country [71] 0 0
Japan
State/province [71] 0 0
Tokyo
Country [72] 0 0
Japan
State/province [72] 0 0
Fukui
Country [73] 0 0
Japan
State/province [73] 0 0
Fukuoka
Country [74] 0 0
Japan
State/province [74] 0 0
Jonan-ku
Country [75] 0 0
Japan
State/province [75] 0 0
Kiyose
Country [76] 0 0
Japan
State/province [76] 0 0
Nagano
Country [77] 0 0
Japan
State/province [77] 0 0
Naka-gun
Country [78] 0 0
Japan
State/province [78] 0 0
Sakai-shi
Country [79] 0 0
Japan
State/province [79] 0 0
Shimonoseki
Country [80] 0 0
Japan
State/province [80] 0 0
Ôsaka
Country [81] 0 0
Korea, Republic of
State/province [81] 0 0
Gyeonggido
Country [82] 0 0
Korea, Republic of
State/province [82] 0 0
Seoul Teugbyeolsi
Country [83] 0 0
Korea, Republic of
State/province [83] 0 0
Incheon
Country [84] 0 0
Korea, Republic of
State/province [84] 0 0
Seoul
Country [85] 0 0
New Zealand
State/province [85] 0 0
Hawkes's Bay
Country [86] 0 0
New Zealand
State/province [86] 0 0
Waikato
Country [87] 0 0
New Zealand
State/province [87] 0 0
Christchurch
Country [88] 0 0
Poland
State/province [88] 0 0
Swietokrzyskie
Country [89] 0 0
Portugal
State/province [89] 0 0
Braga
Country [90] 0 0
Portugal
State/province [90] 0 0
Lisboa
Country [91] 0 0
Spain
State/province [91] 0 0
Barcelona
Country [92] 0 0
Spain
State/province [92] 0 0
Pontevedra
Country [93] 0 0
Spain
State/province [93] 0 0
Girona
Country [94] 0 0
Spain
State/province [94] 0 0
Madrid
Country [95] 0 0
Spain
State/province [95] 0 0
Pamplona
Country [96] 0 0
Spain
State/province [96] 0 0
Sevilla
Country [97] 0 0
Taiwan
State/province [97] 0 0
Chiayi
Country [98] 0 0
Taiwan
State/province [98] 0 0
Douliu
Country [99] 0 0
Taiwan
State/province [99] 0 0
Hsinchu City
Country [100] 0 0
Taiwan
State/province [100] 0 0
Kaohsiung
Country [101] 0 0
Taiwan
State/province [101] 0 0
New Taipei City
Country [102] 0 0
Taiwan
State/province [102] 0 0
Taipei City
Country [103] 0 0
Taiwan
State/province [103] 0 0
Taipei
Country [104] 0 0
Turkey
State/province [104] 0 0
Izmir
Country [105] 0 0
Turkey
State/province [105] 0 0
Kocaeli
Country [106] 0 0
United Kingdom
State/province [106] 0 0
Devon
Country [107] 0 0
United Kingdom
State/province [107] 0 0
West Midlands
Country [108] 0 0
United Kingdom
State/province [108] 0 0
Aberdeen
Country [109] 0 0
United Kingdom
State/province [109] 0 0
Cambridge
Country [110] 0 0
United Kingdom
State/province [110] 0 0
Dundee
Country [111] 0 0
United Kingdom
State/province [111] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Insmed Incorporated
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Insmed Medical Information
Address 0 0
Country 0 0
Phone 0 0
844-4-INSMED
Fax 0 0
Email 0 0
medicalinformation@insmed.com
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT04677569